Reports Q3 revenue $347.456, consensus $350,000. "We’ve hit multiple company milestones this past quarter, as well as further strengthened our management team in key functional areas," said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. "Most notably, we completed enrollment in our Stage 2 trial of FemBloc permanent birth control and strategically updated the FemaSeed de novo trial design, accelerating enrollment for this important program. Approximately 50% of infertility is attributed to male factor and FemaSeed is being studied to offer a cost-effective, efficacious option to existing invasive and expensive treatment alternatives. We also made FemCerv, designed for comprehensive cervical sampling and minimal contamination for the diagnosis of cervical cancer, available to gynecologists. To support all of these high-value programs, we have sales and marketing as well as regulatory and clinical affairs teams well-positioned to lead us towards the next catalysts for the company at this pivotal time."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FEMY:
- Femasys price target lowered to $5 from $8 at H.C. Wainwright
- Femasys provides strategic update on its FemaSeed trial design
- Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
- Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress
- Femasys appoints Christine Thomas as SVP, regulatory, clinical affairs